Related Articles
Oral low-dose dexamethasone for androgen-independent prostate cancer patients
Substitution of anti-androgens and tegafur-uracil combination therapy for castration-resistant prostate cancer: Results of a multi-center randomized phase II study
Predictive implications of nucleoside metabolizing enzymes in premenopausal women with node-positive primary breast cancer who were randomly assigned to receive tamoxifen alone or tamoxifen plus tegafur-uracil as adjuvant therapy
Identification of favorable subgroups for alternative anti‑androgen therapy in castration‑resistant prostate cancer
Prediction of response to preoperative chemoradiotherapy and establishment of individualized therapy in advanced rectal cancer